The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
HYQVIA Takeda Pharmaceuticals Australia Pty Ltd
Product name
HYQVIA
Accepted date
May-2024
Active ingredients
normal immunoglobulin
Proposed indication
For Immunomodulatory therapy in adults and children in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy after stabilistion with IVIG.
Application type
C (new indication)
Publication date
May-2024